iBinom Company
Aiming to get a foothold in the emerging clinical next-gen sequencing market iBinom launched a simple, fast and affordable human genome interpretation service. iBinom Saas platform is an end-to-end genome interpretation solution for diagnostics of Mendelian and non-Mendelian diseases, tumor profiling, and drug response biomarker discovery studies. iBinom uses Amazon EC2, the world fastest proprietary algorithms, unique machine learning technology and special design of medical report to make inherited deceases diagnostics simpler and faster.
Founded Date:
2012
Technology:
Machine Learning
Investor Type:
N/A
Headquarters:
Moscow, Russia
Number Of Exists:
N/A
Funding Status:
Seed
Investment Stage:
N/A
Industry:
Healthcare